To investigate the possible role of GBP2 against apoptosis induced by chemotherapeutics, K562 cells were treated with paclitaxel (Taxol®), a widely used anticancer drug, or imatinib (Greevec®), the first-line treatment for Philadelphia chromosome-positive CML. Here, GBP2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.